| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | Halneuron® chemotherapy induced neuropathic pain (CINP) | Phase 2b | — | Small Molecules | Nervous System | ||
phase 2b data readout example | Halneuron® chemotherapy induced neuropathic pain (CINP) | Phase 2b | — | Small Molecules | Nervous System | ||
phase 2b data readout example | Halneuron® chemotherapy induced neuropathic pain (CINP) | Phase 2b | — | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Dogwood Therapeutics, Inc.$1.5
-0.11 (-6.83%)
D 28Pipeline Score Richly Valued Pharma · Clinical
Market Cap
60.20 M
EPS
-10.60
P/E Ratio
-
Value Trade
142.23 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.67 M
Operating CF
-4.59 M
Total Assets
95.21 M
Total Liabilities
14.58 M
Equity
80.62 M
D/E Ratio
12,345
-7.25 %
Week
18.54 %
1 Month
-40.53 %
3 Month
-69.81 %
6 Month
-98.73 %
5 Year
-99.41 %
All Time
Cash Data
Cash Position
13.23 M
Monthly Burn
1.53 M
Runway
7.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
135.84 K
52 Week Range
1.28 - 9.50
% held by Insiders
74.09 %
% held by Institutions
10.76 %
Enterprise Value
47.11 M
Total Shares
33.32 M
Short %
0.31 %
Float Shares
8.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dogwood Therapeutics, Inc.
147Total events
5Upcoming
36Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 5
TBD
T2Trial Initiation
Forthcoming SP16 IV Phase 1b CINP trial to commence following FDA consultation
Event history 142
Q3 2026
◆Topline ReadoutHalneuronClinical Data
Top-line results expected in Q3 2026
chemotherapy induced neuropathic painsource ↗
Q3 2026
◆Topline ReadoutHalneuronClinical Data
Top line results expected in Q3 2026
chemotherapy induced neuropathic painsource ↗
Q3 2026
◆Enrollment MilestoneHalneuronTrial
Double-blinded portion expected to meet enrollment objectives
chemotherapy induced neuropathic painsource ↗
May 18, 2026
▲OLE InitiatedHalneuronTrial
Commencement of Halneuron CINP Phase 2b long term extension study
chemotherapy induced neuropathic painsource ↗
May 18, 2026
▲Interim AnalysisHalneuronTrial
Pre-planned interim analysis supported continuation of double-blinded Phase 2b study
chemotherapy induced neuropathic painsource ↗
May 14, 2026
▲IND ClearanceSP16IND
FDA acceptance of SP16 Investigational New Drug Application
Chemotherapy Induced Pain and Neuropathysource ↗
May 14, 2026
▲Partnership / LicenseCorporate
Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets
Apr 23, 2026
▲Partnership / LicenseCorporate
Dogwood Therapeutics announces global development and commercialization partnership with PRIDCor for IMC-1 and IMC-2
Apr 15, 2026
▲IND ClearanceSP16IND
FDA acceptance of SP16 IND for CIPPN
chemotherapy-induced pain and peripheral neuropathysource ↗
Q2 2026
◆First Patient DosedSP16Trial
Patient enrollment expected to commence in middle of 2026
chemotherapy-induced pain and peripheral neuropathysource ↗
Q2 2026
◆Full ResultsHalneuronClinical Data
Full results from Phase 2b trial
Chemotherapy-Induced Neuropathic Painsource ↗
Drug Pipeline Intelligence
D28
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 32%
Micro Cap (rank 616 of 905)
Percentile RankDogwood Therapeutics, Inc. faces pipeline headwinds (28/100), with $18M risk-adjusted pipeline value, led by Halneuron in Chemotherapy Induced Neuropathic Pain (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Halneuron Small molecule | Chemotherapy Induced Neuropathic Pain | Phase 2 | NCT06848348 | 11% | $18M | RECRUITING | 240 | FAST | B (66) | Aug 1, 2026 | MODERATE_RISK | MEDIUM May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IMC-1 | Fibromyalgia | 2b | 2022-09-19 | |||
IMC-1 | Fibromyalgia | 2b | 2022-09-19 | |||
IMC-1 | Fibromyalgia | 2b | 2022-09-19 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DWTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
DWTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DWTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DWTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DWTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
DWTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DWTXDogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Dogwood Therapeutics has appointed Iain Dukes, a seasoned biopharma executive, as Chair of its Scientific Advisory Board. Dr. Dukes will guide the company on scientific developments for its innovative pain and neuropathy therapeutics. The company is advancing its lead candidate, Halneuron, into Phase 2b trials, with promising data expected in late 2026.
Read more →DWTXDogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics has announced the start of a Phase 2b long-term extension study for Halneuron®, a treatment for chemotherapy-induced neuropathic pain (CINP). The study follows a positive interim analysis that supports continuing the treatment with Halneuron®. Patients who completed the initial 4-week study can enroll for an additional 12-week period, aimed at assessing ongoing safety and effectiveness. This data will be crucial for the planned Phase 3 submission to the FDA, which is projected to commence in 2027.
Read more →DWTXDogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New
Dogwood Therapeutics reported its financial results for the first quarter of 2026, highlighting significant progress in its clinical pipeline. The Phase 2b trial for Halneuron, aimed at treating chemotherapy-induced neuropathy, is on track for results in fall 2026. Additionally, the FDA has accepted the Investigational New Drug Application for SP16. The company also established a worldwide partnership for its antiviral assets, which holds potential value up to $100 million. Overall, Dogwood demonstrates operational strength despite a reported net loss, which is notably lower than the previous year's figures.
Read more →DWTXDogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics, a biopharmaceutical company, will report its first quarter 2026 financial results on May 14, 2026. The company focuses on developing treatments for pain and neuropathy, with Halneuron in Phase 2b trials and SP16 IV set for a Phase 1b trial. Both candidates target chemotherapy-induced pain and neuropathic disorders.
Read more →DWTXDogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics has entered a global partnership with PRIDCor Therapeutics for the development and commercialization of antiviral assets IMC-1 and IMC-2. This agreement includes potential payments up to $100 million and a tiered royalty of up to 15% on net sales. Dogwood will benefit from the financial support while focusing on its lead products, Halneuron® and SP16. However, the success of this partnership is contingent upon PRIDCor's execution of the development plans.
Read more →DWTXDogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood Therapeutics has announced the FDA's acceptance of its Investigational New Drug application for SP16, a treatment targeting chemotherapy-induced pain and neuropathy. This marks a pivotal step for the company as it progresses into clinical trials, with patient enrollment expected to begin in mid-2026 at the University of Virginia. The SP16 candidate has been designed to reduce inflammation and promote tissue repair, addressing the high incidence of chemotherapy-induced peripheral neuropathy. Significant funding for the upcoming trial comes from a $2.5 million grant awarded by the National Cancer Institute.
Read more →DWTXCEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026 Progress Report ALPHARETTA, Ga.
Dogwood Therapeutics (DWTX) has provided a corporate update highlighting its advancements in developing non-opioid treatments for cancer-related pain and neuropathy. CEO Greg Duncan expressed optimism regarding the company's pipeline, especially focusing on the lead candidate Halneuron, which is currently in Phase 2b trials and has received FDA fast track designation. The upcoming year is seen as promising for both shareholders and patients as the company works towards executing critical milestones in its development programs. Potential challenges remain due to inherent risks in predicting clinical study outcomes and other uncertainties.
Read more →DWTXDogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results ATLANTA, Ga.
Dogwood Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting notable progress in its clinical trials and reduced expenses. The company successfully recruited 143 patients for its ongoing Halneuron Phase 2b trial and launched a Phase 2b extension trial. Despite a substantial net loss of $35.5 million for the year, it showed an improvement compared to the previous year's loss. Additionally, recent financing is expected to fund operations through key clinical milestones.
Read more →DWTXDogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Dogwood Therapeutics has announced that it has surpassed 50% enrollment in its ongoing Phase 2b trial for Halneuron, aimed at treating chemotherapy-induced neuropathic pain. The trial is on track to deliver top line results in Q3 2026. Early data suggests Halneuron is well tolerated, with a low dropout rate, and shows promise in pain improvement compared to placebo.
Read more →DWTXCEO Letter to Dogwood Therapeutics Shareholders: The Year in Review, The Year Ahead ALPHARETTA, Ga.
Dogwood Therapeutics has issued a corporate update from CEO Greg Duncan reflecting on the progress made in 2025 and outlining future milestones for 2026. The company focuses on developing non-opioid treatments for cancer-related pain and neuropathy, with promising candidates like Halneuron in Phase 2b development. The letter conveys optimism for the upcoming year and highlights the efforts made to enhance the standard of care for affected patients. However, it also acknowledges inherent risks associated with forward-looking statements.
Read more →DWTXDogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dogwood Therapeutics, Inc. has announced a financing deal of up to $26.8 million to support the development of its lead product, Halneuron®, through Phase 2b trials. The funding includes a registered direct offering and a private placement, with a total of 4,386,037 shares being issued. The company aims to utilize the proceeds to advance clinical development and strengthen its research portfolio.
Read more →DWTXDogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dogwood Therapeutics has announced positive interim results from its Phase 2b clinical trial for Halneuron® in treating chemotherapy-induced neuropathic pain (CINP). An independent statistical review highlighted that patients receiving Halneuron® exhibited significant pain improvement compared to those on placebo. The trial featured a low dropout rate of approximately 4.4%, indicating good tolerability. The company anticipates top-line results to be available in Q3 2026 as they push towards potentially groundbreaking developments for CINP therapies.
Read more →DWTXDogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Therapeutics has filed for new intellectual property protection for its synthetic Halneuron®, which could extend exclusivity until 2045. The new synthetic manufacturing process aims to enhance production efficiency and lower costs. Halneuron® is currently in Phase 2b development as a non-opioid treatment for chemotherapy-induced neuropathic pain and has received fast track designation from the FDA.
Read more →DWTXDogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics reported its Q3 2025 financial results, highlighting the enrollment of 100 patients in the Halneuron® Phase 2b trial. The company secured a worldwide license for SP16, a new treatment for cancer-related pain. Despite a net loss of $15.7 million, Dogwood remains optimistic about upcoming milestones, including an interim analysis in Q4 2025.
Read more →DWTXNASDAQ: DWTX Q4 2025 Update Deep Commitment to Advancing First-in-Class New Therapeutic Treatments for Cancer Patients Suffering from Neuropathy NASDAQ: DWTX CONFIDENTIAL – Dogwood Therapeutics, Inc. 2 Forward-Loo
Dogwood Therapeutics, Inc. is making strides in developing treatments for chemotherapy-induced neuropathy (CINP) with two key programs: Halneuron and SP16. Halneuron, currently in Phase 2b trials, is a Nav1.7 channel blocker that aims to provide effective pain relief from CINP, while SP16, an LRP1 agonist, seeks to offer neuroprotection during chemotherapy. Recent updates highlight the recruitment of patients for the Halneuron study and the filing of new intellectual property for SP16. With NCI funding supporting these initiatives, Dogwood is positioned to advance its therapies towards market entry.
Read more →DWTXDogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
Dogwood Therapeutics has obtained an exclusive, royalty-free license for SP16, a first-in-class LRP1 agonist, to manage cancer-related pain. This license will facilitate the development of SP16 in a Phase 1b study, funded by the National Cancer Institute, targeting chemotherapy-induced neuropathy. The company aims to leverage this opportunity to enhance its research pipeline and address significant unmet medical needs.
Read more →DWTXDogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Dogwood Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Greg Duncan is scheduled for a fireside chat on September 5, 2025. The company is focused on developing treatments for pain and fatigue-related disorders, with promising data expected from ongoing clinical studies.
Read more →DWTXDogwood Therapeutics Reports Second Quarter 2025 Financial Results - Enrollment to-date of 52 patients in the ongoing Halneuron Phase 2b Trial - - Halneuron Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study i
Dogwood Therapeutics reported its financial results for Q2 2025, highlighting the enrollment of 52 patients in the ongoing Halneuron Phase 2b trial. The interim data readout for the trial remains on schedule for Q4 2025, and the treatment has exhibited a low discontinuation rate, suggesting good tolerance among participants. The company has a cash reserve of $13.4 million, ensuring operational capabilities through the first quarter of 2026. However, financial losses have increased compared to the previous year, raising concerns about the sustainability of operations amid rising expenses.
Read more →DWTXDogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Dogwood Therapeutics has successfully enrolled the first 50 patients in its Phase 2b trial for Halneuron, aimed at treating chemotherapy-induced neuropathic pain. The trial is on track for interim analysis in Q4 2025, with a low discontinuation rate observed among participants. The company highlights the unique mechanism of Halneuron as a sodium channel inhibitor, differentiating it from other treatments.
Read more →DWTXDogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Dogwood Therapeutics, a development-stage biotechnology company, will report its second quarter 2025 financial results on August 13, 2025. The company focuses on developing new treatments for pain and fatigue-related disorders, leveraging its lead candidate, Halneuron®, and an antiviral program combining anti-herpes treatments. Upcoming interim data from the Phase 2 study of Halneuron® are expected in Q4 2025, along with advancements in its antiviral candidates aimed at Long-COVID and fibromyalgia.
Read more →DWTXDogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Dogwood Therapeutics will present at the Sidoti Small-Cap Virtual Conference on June 11-12, 2025. CEO Greg Duncan will provide a corporate overview and is available for one-on-one meetings. The company focuses on developing non-opioid treatments for pain and fatigue-related disorders, with promising candidates like Halneuron® and IMC-2 in their pipeline.
Read more →DWTXDogwood Therapeutics Announces First Quarter 2025 Financial Results - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron Chemothera
Dogwood Therapeutics reported its first-quarter financial results for 2025, highlighting the commencement of patient dosing in its Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain. The company has $17.5 million in cash, providing operational stability through Q1 2026. However, its net loss increased notably to $12.2 million compared to $1.3 million in the previous year's quarter, alongside rising operational expenses. The company also sees a potential to expand its research pipeline to address other significant pain conditions.
Read more →DWTXDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Dogwood Therapeutics has confirmed compliance with Nasdaq's equity requirements after previously falling below the minimum threshold. The company has a robust cash position and is actively conducting clinical trials for its lead candidate, Halneuron®, aimed at treating chemotherapy-induced neuropathic pain. Interim data from these trials is expected in Q4 2025.
Read more →DWTXDogwood Therapeutics, Inc. Regains Nasdaq Compliance ATLANTA, Ga.
Dogwood Therapeutics, Inc. has announced that it has regained its compliance with Nasdaq's minimum stockholder equity requirement after completing a series of financial transactions. These include a significant debt exchange agreement that eliminated about $19.9 million in debt, alongside a stock sale that generated approximately $4.8 million in revenue. The company's current cash position is strong, bolstering its ability to pursue its mission of developing new treatments for pain and fatigue-related disorders. Additionally, Dogwood is progressing with clinical studies for its lead candidates, Halneuron and IMC programs, focusing on pain reduction and antiviral treatments.
Read more →DWTXDogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results -Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial -
Dogwood Therapeutics reported its financial results for the fourth quarter and full year of 2024, highlighting its ongoing advancements in the Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b trial. The company commenced patient dosing and expects interim data to be released in Q4 2025, marking a critical milestone. Recently completed capital raises have improved Dogwood's liquidity and facilitated a conversion of debt to equity, strengthening its financial position. However, Dogwood also reported increased net losses and elevated expenses due to operational expansions.
Read more →DWTXDogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics has announced the dosing of the first patient in its Phase 2b clinical trial for Halneuron, aimed at treating neuropathic pain resulting from chemotherapy. The trial, named HALT-CINP, intends to recruit 100 patients by the end of 2025, allowing for an interim analysis of results. Halneuron is a sodium channel inhibitor that has previously shown promise in reducing cancer-related pain without significant risk of addiction. This development marks a significant step forward for Dogwood in its pursuit of non-opioid pain management solutions.
Read more →DWTXDogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules Proceeds from today's financing, when added to existing cash, fund operation
Dogwood Therapeutics, Inc. has announced the pricing of a $4.8 million registered direct offering of common stock, priced at $8.26 per share, to institutional investors. The proceeds from this offering, expected to close on March 14, 2025, will support operational funding through Q1 2026 and advance the clinical development of its lead candidate, Halneuron. The company anticipates announcing interim data from its Phase 2b chemotherapy-induced neuropathic pain trial in Q4 2025. This financing effort aligns with Dogwood's strategy to enhance its pipeline of non-opioid pain treatments.
Read more →DWTXDogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward Largest shareholder, CK Life Sciences Int'l., (Holdings) Inc. agrees to conversion of debt
Dogwood Therapeutics, Inc. has announced the conversion of $19.5 million in existing debt to equity, facilitated by its largest shareholder, CK Life Sciences Int'l. (Holdings) Inc. This move eliminates all existing debt from Dogwood's balance sheet, bolstering its financial position as it gears up for patient recruitment in its Phase 2b clinical trial for Halneuron, a novel treatment for chemotherapy-induced neuropathic pain. The decision reflects CK Life Sciences' confidence in Dogwood's management and the clinical potential of Halneuron, which has demonstrated a promising safety profile in previous studies.
Read more →DWTXDogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
Dogwood Therapeutics, a biopharmaceutical company, announced the expected initiation of patient dosing in its Phase 2b trial for Halneuron when evaluating its efficacy in treating chemotherapy-induced neuropathy (CINP) in Q1 2025. Halneuron, a new Nav 1.7 inhibitor, has shown promise in previous trials with significant pain reduction and an acceptable safety profile. The move is part of an effort to address a notable gap in effective treatments for chronic neuropathic pain in cancer patients, estimated to be valued at approximately $1.5 billion. The trial aims to provide further insights into Halneuron's potential as a non-opioid alternative to existing pain management options.
Read more →DWTXDogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Dogwood Therapeutics, Inc. announced positive results from their BHC IMC-2 Long-COVID study, indicating that the low dose combination of valacyclovir and celecoxib significantly reduced fatigue and sleep disturbances. This study's insights will guide the design of a larger, planned Phase 2 study aimed at about 200 participants. Although the high dose did not perform well due to adverse gastrointestinal events, the overall findings suggest IMC-2 holds promise as a viable treatment option for Long-COVID symptoms, a condition currently lacking FDA-approved therapies.
Read more →DWTXDogwood Therapeutics Announces Third Quarter 2024 Financial Results - Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced its third quarter financial results, reporting a significant expansion of its pipeline following the recent merger. The company is advancing clinical development, notably for its non-opioid treatment Halneuron for neuropathic pain, and is expecting results from key trials in the upcoming months. However, it reported an increase in net loss and indicated a need for additional funding to sustain operations through 2025.
Read more →DWTXDogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
Dogwood Therapeutics, formerly Virios Therapeutics, will report its third quarter 2024 financial results on November 7, 2024, prior to market open. Management plans to host a webcast and conference call to discuss the results and provide corporate updates. The company focuses on developing new treatments for pain and fatigue-related disorders, with various projects in different stages of clinical development, including non-opioid analgesics and antiviral therapies targeting reactivated herpes viruses.
Read more →DWTXDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Dogwood Therapeutics, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirements, closing the matter for continued listing. Key upcoming events include the expected top-line results from the phase 2a study of IMC-2 for Long-COVID slated for mid-November 2024 and ongoing integration efforts following the recent acquisition of Pharmagesic. The company is actively developing a robust pipeline of drugs targeted at pain and fatigue-related disorders, including a proprietary non-opioid analgesic and an antiviral program.
Read more →DWTXFacebook: https://www.facebook.com/dogwoodther Forward-Looking Statements Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of
Dogwood Therapeutics, Inc. (DWTX) has announced its compliance with the Nasdaq minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market. The company, focused on pain and fatigue-related disorders, is advancing its development programs, with expectations for interim data from its Phase 2 CINP study in the latter half of 2025. Furthermore, top-line data from an ongoing Phase 2 study related to Long-COVID is anticipated in mid-November 2024, signaling ongoing progress in its product pipeline.
Read more →DWTXVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") Strategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., r
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. announced a definitive share exchange agreement to combine operations and form Dogwood Therapeutics, Inc. The new entity will prioritize the clinical development of three assets: Halneuron for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for Long-COVID. The transaction includes a $19.5 million financing commitment from CK Life Sciences and a reverse stock split of 25-for-1, effective October 9, 2024. Dogwood's future plans involve a series of clinical milestones and potential partnerships to enhance its drug development ambitions.
Read more →DWTXVirios Therapeutics Announces Second Quarter 2024 Financial Results - Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib
Virios Therapeutics announced its financial results for the second quarter of 2024, highlighting the completion of enrollment in its Long-COVID phase 2a study at the Bateman Horne Center. The company anticipates top-line results from this study by October 2024, which will inform the design of a planned Phase 2b study. Virios reported a net loss of $1.0 million for the quarter and indicated that it has enough cash to fund operations into the first quarter of 2025. The company focuses on developing antiviral therapies for chronic diseases like fibromyalgia and Long-COVID.
Read more →DWTXVirios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study ATLANTA, GA
Virios Therapeutics has announced the pricing of a public offering of 8,500,000 shares of common stock at $0.20 per share, aimed at raising approximately $1.7 million. The funds are intended for preparatory activities for the upcoming IMC-2 Long-COVID Phase 2b study, as well as for general corporate purposes. This offering is expected to close on May 22, 2024, subject to customary conditions. The public offering is conducted under an effective shelf registration statement previously filed with the SEC.
Read more →DWTXVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir a
Virios Therapeutics announced its financial results for Q1 2024 and provided a corporate update. The company expects to release top-line results from a phase 2 study investigating valacyclovir and celecoxib for Long-COVID in the second half of 2024. Financially, Virios reported a reduced net loss compared to the same period in 2023 and maintains sufficient cash resources to support its operations into the fourth quarter of 2024. The CEO highlighted the increasing need for effective Long-COVID therapies, stressing the potential impact of their approach on affected individuals.
Read more →DWTXVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results ATLANTA, Ga.
Virios Therapeutics announced its financial results for the fourth quarter and full year of 2023, highlighting a significant decrease in research and development expenses and a reduced net loss compared to the previous year. The company has reached an agreement with the FDA to use fatigue response as a primary endpoint in evaluating its treatment IMC-2 for Long-COVID symptoms. However, despite positive developments, Virios continues to face financial losses, underscoring the challenges ahead while it seeks to advance its antiviral therapies.
Read more →DWTXVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga.
Virios Therapeutics has announced its financial results for the third quarter of 2023, demonstrating a reduced net loss of $1.2 million compared to the loss of $2.6 million in Q3 2022. The company's focus remains on advancing antiviral therapies for conditions related to reactivated viruses, such as fibromyalgia and Long-COVID. The financial results indicate a decrease in both research and development and general administrative expenses. Virios holds cash reserves of $4.8 million, enough to sustain operations through mid-2024.
Read more →DWTXVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Continued Progress in Expanding and Advancing Clinical Pipeline - - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga.
Virios Therapeutics announced its financial results for Q2 2023, highlighting progress in its clinical pipeline, particularly for IMC-1 and IMC-2. The company is advancing IMC-1 into Phase 3 for fibromyalgia and IMC-2 into Phase 2 for Long-COVID. Financial results show a reduction in net loss compared to the same period last year, yet the company’s cash reserves have decreased. A conference call is scheduled to discuss these results and future plans.
Read more →DWTXVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia ATLANTA, Ga.
Virios Therapeutics has announced plans to advance its lead candidate IMC-1 to Phase 3 development as a treatment option for fibromyalgia. Following an initial review, the FDA deemed the company's chronic toxicology studies adequate for supporting IMC-1's safety at the proposed dosage. The company aims to initiate a pharmacokinetic and food effect study this year and plans to begin enrollment for the Phase 3 study in mid-2024, following the completion of the pK study. More details about the Phase 3 program will be shared in an earnings update on August 10, 2023.
Read more →DWTXVirios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept S
Virios Therapeutics has announced promising results from a study on the combination of valacyclovir and celecoxib in addressing Long-COVID symptoms. Female patients demonstrated significant clinical improvements in fatigue, pain, and overall health after a 14-week treatment compared to a control group. Virios plans to engage with the FDA to discuss advancing this treatment option formally. The potential impact of this treatment could be substantial, given the wide prevalence of Long-COVID symptoms affecting millions globally.
Read more →DWTXSent via Electronic Delivery to : angela@virios.com
Virios Therapeutics, Inc. has successfully regained compliance with the Nasdaq Listing Rule 5550(a)(2) after satisfying the minimum bid price requirement. The company's stock closed at $1.00 or above for a consecutive period of 10 business days, which resolves the previously noted compliance issue. This development indicates a positive turnaround for the company's market position.
Read more →DWTXVirios Therapeutics Announces First Quarter 2023 Financial Results ATLANTA, Ga.
Virios Therapeutics reported its financial results for the first quarter of 2023, highlighting constructive discussions with the FDA regarding its IMC-1 program for fibromyalgia. The company's net loss decreased to $1.5 million compared to $4.0 million in Q1 2022, attributed to a reduction in operating expenses. As of March 31, 2023, Virios has $5.3 million in cash, which the company believes will sustain operations into mid-2024, although future clinical trials will necessitate additional funding.
Read more →DWTXVirios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results ATLANTA, Ga.
Virios Therapeutics reported its fourth quarter and full year 2022 financial results, showing a substantial reduction in net losses compared to 2021. The company's research and development expenses fell significantly due to reduced clinical trial costs, including a notable decrease in expenses related to the FORTRESS study. With cash reserves totaling $7.0 million, Virios anticipates sufficient resources to sustain its operations and exploratory programs into mid-2024. However, the ongoing need for additional funding for future projects poses a potential challenge.
Read more →DWTXNew Scientific Paradigm Exploring Herpes Virus Activation as Potential Underlying Cause of Fibromyalgia, Long COVID and Other Chronic Conditions Nasdaq: VIRI November 2022 NASDAQ: VIRI Forward Looking Statements 2 Ȃ
Apostolou et al, Frontiers in Immunology , 2022; Traylen, Christopher Met al, Future virology, 2011; Bo Diao , Chenhui Wang, et al., 2019 NASDAQ: VIRI Strong IP Portfolio with 21 Issued Patents to 2033 24 Four Issued US IMC - 1 P atents - Two Composition of M a tter P a tents - D
Read more →DWTXVirios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update - FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatm
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update - FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatment Benefits - - Company Believes FORTRESS Safety Data Su
Read more →DWTXVirios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia ATLANTA, Ga.
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia ATLANTA, Ga., September 19, 2022 - Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat
Read more →DWTXVirios Therapeutics, Inc. Announces Proposed Public Offering ATLANTA, Ga.
Virios Therapeutics, Inc. Announces Proposed Public Offering ATLANTA, Ga., September 19, 2022 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases
Read more →DWTXVirios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Top Line FORTRESS Study Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga.
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Top Line FORTRESS Study Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga., August 11, 2022 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a
Read more →DWTXVirios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update - Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 - - Conference Call Today at 8:30 a.
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update - Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga., May 12, 2022 -- Virios Therapeutic
Read more →DWTXVirios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 - - Pipeline Expanded with IMC-2
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update ATLANTA, Ga., March 17, 2022 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to
Read more →DWTXHSV-1virus Virios Therapeutics, Inc. Nasdaq: VIRINew Scientific Paradigm ExploringHerpes Virus Activation asPotential Underlying Cause of Fibromyalgia, Long COVIDand Other Chronic ConditionsCorporate Update Q1, 20211 For
Exercise Price of $9.03/share, **Includes officers and directorsNasdaq: VIRI Virios Therapeutics Summary19Nasdaq: VIRIFocused on Two Significant Commercial Opportunities: The Large, Dissatisfied Fibromyalgia(FM) Market: 2%-8% of the Population Long COVID, a Rapidly Emerging Unmet
Read more →DWTXVirios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Over 200 Patients Enrolled in Fibromyalgia Phase 2b Trial - Filed Investigational New Drug Application with FDA to Assess
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update ATLANTA, Ga., November 11, 2021 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilit
Read more →DWTXHSV‐1 virus Virios Therapeutics, Inc. (Nasdaq: “VIRI”) New Scientific Paradigm Exploring Herpes Simplex 1 (HSV‐1) Virus Activation as Potential Underlying Cause of Fibromyalgia and Other Chron
Exercise Price of $9.31/share ***Includes officers and directors Virios Therapeutics Summary 22 Virios Team and Board of Directors Have Led Development or Commercialization for Two of Three FDA Approved FM Medicines The Fibromyalgia (FM) Market is Large, but Dissatisfied Highligh
Read more →DWTXVirios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update ATLANTA, Ga.
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update ATLANTA, Ga., August 12, 2021 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitati
Read more →DWTXHSV-1 virus Virios Therapeutics, Inc. (Nasdaq: “VIRI”) New Scientific Paradigm Exploring Herpes Simplex 1 (HSV-1) Virus Activation as Potential Underlying Cause of Fibromyalgia and Other Chronic Conditions
Exercise Price of $9.80/share Virios Therapeutics Summary 18 Virios Team and Board of Directors Have Led Development or Commercialization for Two of Three Approved FM Medicines The Fibromyalgia (FM) Market is Large, but Dissatisfied Highlighting Significant Commercial Potential f
Read more →DWTXVirios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update ATLANTA, Ga.
Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update ATLANTA, Ga., May 13, 2021 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases assoc
Read more →DWTXHSV-1 virus Virios Therapeutics, Inc. (Nasdaq: “VIRI”) New Scientific Paradigm Exploring Herpes Simplex 1 (HSV-1) Virus Activation as Potential Underlying Cause of Fibromyalgia (FM) and Other Chronic Condit
Exercise Price of $9.80/share Virios Therapeutics Summary 19 Virios Team and Board of Directors Have Deep Experience in Developing and Commercializing FM and Antiviral Medicines The FM Market is Large, but Dissatisfied Significant Commercial Potential for Differentiated New FM Tr
Read more →DWTXVirios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update ATLANTA, Ga.
Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update ATLANTA, Ga., March 18, 2021 -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to tre
Read more →Competitive Position
How DWTX ranks across every disease it competes inCompetitive Position is a premium feature
See how DWTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial